About
About Acacia Pharma Group plc
Acacia Pharma Group plc discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, invasive procedures, or chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an intravenous remimazolam and reversible IV sedative designed for use during invasive medical procedures, such as colonoscopy and bronchoscopy; and APD403, a selective dopamine antagonist amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.
Visit company website
5 years, 4 months ago
Acacia Pharma Group plc is currently in a long term downtrend where the price is trading 8.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Its net income has dropped by 56.3% to $-15M since the same quarter in the previous year.
Finally, its free cash flow fell by 149.6% to $-7M since the same quarter in the previous year.
Based on the above factors, Acacia Pharma Group plc gets an overall score of 1/5.